CD44 expression dynamics in the corpus callosum after cuprizone-induced demyelination
DOI:
https://doi.org/10.2478/AMB-2026-0006Keywords:
CD44, cuprizone model, multiple sclerosis, corpus callosumAbstract
Abstract. Background: CD44, a hyaluronan receptor expressed by glial and progenitor cells, has been implicated in neuroinflammation and impaired remyelination. We investigated changes in CD44 expression and cell morphology in the corpus callosum (CC) during toxin-induced demyelination and subsequent spontaneous remyelination. Materials and Methods: Thirty adult male C57BL/6 mice were assigned to three groups (n = 10/group): control, demyelination (0.2% cuprizone for 5 weeks), and remyelination (5 weeks of cuprizone followed by 5 weeks of recovery). CD44 immunohistochemistry was performed on coronal CC sections. Quantification was carried out in the medial CC (three sections per animal, five non-overlapping fields per section; total n = 150 visual fields per group). Morphological features of CD44+ cells were assessed qualitatively. Group differences were analyzed using the Kruskal–Wallis test with Dunn’s post-hoc comparisons. Results: In the controls, CD44 immunoreactivity was sparse and primarily localized to the perinuclear region. Demyelination resulted in a marked increase in CD44 labeling, with CD44+ cells being substantially more numerous and exhibiting multiple cytoplasmic processes consistent with an activated astrocytic phenotype. During remyelination, CD44 labeling persisted but with fewer and shorter processes, indicating partial reversion toward a less activated morphology. Mean CD44+ cells per field were 19 (control), 57 (demyelination), and 32 (remyelination), corresponding to densities of 183, 528, and 426 cells/mm², respectively (control < remyelination < demyelination). Differences among groups were significant (Kruskal-Wallis, p < 0.001), and all pairwise comparisons were significant (Dunn’s test, p < 0.001). Conclusions: Cuprizone-induced demyelination triggers robust upregulation of CD44 and an activated astrocyte–like morphology in the CC, which partially normalizes during remyelination. These results highlight the dynamic regulation of CD44 during white matter injury and recovery and support further investigation into its mechanistic role in remyelination.
References
Kipp M, Nyamoya S, Hochstrasser T, Amor S. Multiple sclerosis animal models: a clinical and histopathological perspective. Brain Pathol, 2017, 27(2):123-137. doi: 10.1111/bpa.12454.
Seitaridou Y, Dimitrova M, Chamova T, et al. Cost-effectiveness of multiple sclerosis therapies – a literature review. Acta Medica Bulg, 2022, 49(4):69-80. doi: 10.2478/amb-2022-0046.
Hauser SL, Aubert C, Burks JS, et al. Analysis of human Tlymphotrophic virus sequences in multiple sclerosis tissue. Nature, 1986, 322(6075):176-7. doi: 10.1038/322176a0.
Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol, 2001, 11(1):107-16. doi: 10.1111/j.1750-3639.2001.tb00385.x.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol, 2003, 4(1):33-45. doi: 10.1038/nrm1004.
Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science, 2002, 296(5565):155-8. doi: 10.1126/science.1069659.
Dzwonek J, Wilczynski GM. CD44: molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci, 2015, 9:175. doi: 10.3389/fncel.2015.00175.
Geloso MC, Ria F, Corvino V, Di Sante G. Expression of CD44 and its spliced variants: innate and inducible roles in nervous tissue cells and their environment. Int J Mol Sci, 2025, 26(17):8223. doi: 10.3390/ijms26178223.
Girgrah N, Letarte M, Becker LE, et al. Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis. J Neuropathol Exp Neurol, 1991, 50(6):779-92. doi: 10.1097/00005072-199111000-00009.
Back SA, Tuohy TM, Chen H, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med, 2005, 11(9):966-72. doi: 10.1038/nm1279.
Naruse M, Shibasaki K, Yokoyama S, et al. Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One. 2013;8(1):e53109. doi: 10.1371/journal.pone.0053109.
Sawada R, Nakano-Doi A, Matsuyama T, et al. CD44 expression in stem cells and niche microglia/macrophages following ischemic stroke. Stem Cell Investig. 2020 Mar 10;7:4. doi: 10.21037/sci.2020.02.02.
Reinbach C, Stadler MS, Pröbstl N, et al. CD44 expression in the cuprizone model. Brain Res, 2020, 1745:146950. doi: 10.1016/j.brainres.2020.146950.
Flynn KM, Michaud M, Madri JA. CD44 deficiency contributes to enhanced experimental autoimmune encephalomyelitis: a role in immune cells and vascular cells of the blood-brain barrier. Am J Pathol. 2013 Apr;182(4):1322-36. doi: 10.1016/j.ajpath.2013.01.003.
Landzhov B, Gaydarski L, Stanchev S, et al. A Morphological and behavioral study of demyelination and remyelination in the cuprizone model: Insights into APLNR and NG2+ cell dynamics. Int J Mol Sci, 2024, 25(23):13011. doi: 10.3390/ijms252313011.
Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates. 2nd ed. Academic Press. Cambridge, MA, USA, 2001, 55–63.
Bradford BM, Walmsley-Rowe L, Reynolds J, et al. Cell adhesion molecule CD44 is dispensable for reactive astrocyte activation during prion disease. Sci Rep, 2024, 14(1):13749. doi: 10.1038/s41598-024-63464-3.
Kanaan A, Farahani R, Douglas RM, et al. Effect of chronic continuous or intermittent hypoxia and reoxygenation on cerebral capillary density and myelination. Am J Physiol Regul Integr Comp Physiol, 2006, 290(4):R1105-14. doi: 10.1152/ajpregu.00535.2005
Downloads
Published
Issue
Section
License
Copyright (c) 2026 L. Gaydarski, K. Petrova, G. P. Georgiev, B. Landzhov (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica